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Background. Anxiety and depression are common in the modern world, and there is growing demand for alternative therapies
such as meditation. Meditation can decrease perceived stress and increase general well-being, although the physiological
mechanism is not well-characterized. Endocannabinoids (eCBs), lipid mediators associated with enhanced mood and reduced
anxiety/depression, have not been previously studied as biomarkers of meditation effects. Our aim was to assess biomarkers (eCBs
and brain-derived neurotrophic factor [BDNF]) and psychological parameters after a meditation retreat. Methods. )is was an
observational pilot study of adults before and after the 4-day Isha Yoga Bhava Spandana Program retreat. Participants completed
online surveys (before and after retreat, and 1 month later) to assess anxiety, depression, focus, well-being, and happiness through
validated psychological scales. Voluntary blood sampling for biomarker studies was done before and within a day after the retreat.
)e biomarkers anandamide, 2-arachidonoylglycerol (2-AG), 1-arachidonoylglycerol (1-AG), docosatetraenoylethanolamide
(DEA), oleoylethanolamide (OLA), and BDNF were evaluated. Primary outcomes were changes in psychological scales, as well as
changes in eCBs and BDNF. Results. Depression and anxiety scores decreased while focus, happiness, and positive well-being
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scores increased immediately after retreat from their baseline values (P< 0.001). All improvements were sustained 1 month after
BSP. All major eCBs including anandamide, 2-AG, 1-AG, DEA, and BDNF increased after meditation by > 70% (P< 0.001).
Increases of ≥20% in anandamide, 2-AG, 1-AG, and total AG levels after meditation from the baseline had weak correlations with
changes in happiness and well-being. Conclusions. A short meditation experience improved focus, happiness, and positive well-
being and reduced depression and anxiety in participants for at least 1 month. Participants had increased blood eCBs and BDNF,
suggesting a role for these biomarkers in the underlying mechanism of meditation. Meditation is a simple, organic, and effective
way to improve well-being and reduce depression and anxiety.
1. Introduction
In the modern world, stress and anxiety have become
synonymous with success and productivity. Over the course
of a lifetime, almost half of Americans are estimated to have
a mental disorder such as anxiety (>25% incidence) or mood
disorder (>20% incidence) [1, 2]. )ere is increasing interest
and accessibility of nonpharmaceutical treatment options
for these disorders, such as meditation, counseling, and
lifestyle changes (e.g., diet, regular exercise). Meditation is
increasingly being recognized as a simple and effective tool
to decrease perceived stress and increase general well-being
[3].
Although certain benefits of meditation have been
widely acknowledged, the physiological basis and underlying
mechanisms have not been well-characterized. Cortisol
levels may be reduced [4–7], and the neuroregulator brain-
derived neurotrophic factor (BDNF) has been shown to
increase with meditative practices [6, 8–10]. Following a 3-
month Isha yoga and meditation retreat, participants had
nearly a 3-fold increase in mean BDNF. Increased BDNF
signaling, and thus enhanced neurogenesis and/or neuro-
plasticity, was associated with improved resilience and well-
being. Decreases in inflammatory biomarkers, including
interleukin- (IL-) 6, C-reactive protein and tumor necrosis
factor- (TNF-) α, and increases in β-endorphins have also
been shown with various meditation/yoga practices [11].
Endocannabinoids (eCBs) are lipid mediators found in
the brain and peripheral tissues that mimic the action of Δ9
-tetrahydrocannabinol (THC) [12]. )e eCBs N-arach-
idonoylethanolamine (AEA or anandamide) and 2-arach-
idonoylglycerol (2-AG) have been associated with enhanced
mood and feelings of blissfulness. )e term “anandamide”
was even derived from Sanskrit (“ananda” meaning bliss) for
its cannabimimetic effects. Other eCBs include 1-arach-
idonoylglycerol (1-AG), docosatetraenoylethanolamide
(DEA), and oleoylethanolamide (OLA) [12]. Serum levels of
both anandamide and 2-AGmay be reduced in patients with
depression and anxiety, and the eCB system plays a fun-
damental role in emotional homeostasis [13]. We hypoth-
esized that eCBs may be involved in the underlying
mechanisms leading to the beneficial effects of meditation.
To gain greater insights into the psychological and
physiological effects of meditation, we evaluated participants
at Bhava Spandana Program (BSP), an experiential program
leading to deep states of meditativeness in just a short period
of time. In Sanskrit, “Bhava” means “sensation” and
“Spandana” can be loosely translated as “resonance.” Es-
sentially, it means “resonance with life.” )e program [14] is
a 4-day advanced yoga and meditation retreat held at the
Isha Institute of Inner Sciences, located in Tennessee in the
USA. )e prerequisite for participating in the BSP is
completion of the Inner Engineering program offered
worldwide. )e Inner Engineering program teaches par-
ticipants a 21-minute yoga and meditation practice called
Shambhavi Mahamudra [15], an Inner Engineering Level 1
program, which reduces stress and improves well-being [3].
Other Isha Yoga meditation programs have shown benefits
including increased gamma brainwave amplitude, heart rate
variability, sympathovagal balance, BDNF, and cortisol
awakening response [16–18].
)e BSP is a 4-day, 3-night, residential program offered
to those who have been initiated into Shambhavi Maha-
mudra. )is advanced meditation program is designed to
provide the opportunity to go beyond the limitations of body
and mind and experience higher levels of consciousness.
Bhava Spandana offers the experience of a world of un-
bounded love and joy.
)rough powerful processes and meditations, BSP cre-
ates an intensely energetic situation, where individuality and
the limitations of the5 sense organs can be transcended,
creating an experience of oneness and resonance with the
rest of existence. Humans have lived within the limitations
of human senses. Bhava Spandana is like giving one a lift or
jump over the wall to have a peep at life beyond the limi-
tations of the five sense perceptions. Past BSP participants
have described feelings of blissfulness, ecstasy, intense
happiness, inclusive perception, and higher states of con-
sciousness during and after the program.
Our hypothesis was that BSP meditation would signif-
icantly reduce depression and anxiety and improve happi-
ness and positive well-being in the short-term as well as in
the long-term. Furthermore, these changes in psychological
well-being are associated with objective changes in blood
eCB and BDNF levels. )is study specifically aimed (a) to
assess the impact of this 4-day guided, experiential medi-
tation retreat on mental health and well-being (happiness,
awareness, well-being, anxiety, and depression), (b) to
correlate reported psychological changes with objective
blood biomarkers (eCBs and BDNF) immediately after the
retreat, and (c) to assess any persistent impact on partici-
pants’ psychological well-being one month after the retreat.
2. Materials and Methods
2.1. Study Population. In October 2017, adult participants
(≥18 years) were registered to participate in the 4-day BSP
meditation program at Isha Institute of Inner-Sciences,
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McMinnville, Tennessee, USA. All registrants received an
e-mail which invited them to participate in an online survey
2 weeks before the meditation program. Participation in the
study was voluntary. Individuals who were unable to read
and/or comprehend the consent forms were excluded. For
the blood biomarker subset of the study, individuals were
excluded if they reported use of active marijuana, opioid, or
other illegal drugs, or if they were taking antidepressant
medication. )e protocol was reviewed and approved by
Institutional Review Board of Indiana University School of
Medicine. All participants gave electronic informed consent.
2.2. Meditation Program. )e BSP is a 4-day advanced yoga
and meditation program designed to enhance participants’
perception and sensitivity to life by going beyond the limita-
tions of body and mind and experiencing higher levels of
consciousness [14]. Participants are required to complete an
online or in-person prerequisite program (Inner Engineering)
that includes ShambhaviMahadmudra kriya yoga practice [15].
2.3. Surveys. Participants completed the preprogram
(“baseline”) survey within 2 weeks before the retreat and
postprogram (“immediately after retreat”) survey within 2
weeks after the retreat, and a 1-month follow-up survey.
)ese surveys included scales that have well-established
reliability and validity in the literature. Depression is
measured by the 20-item Center for Epidemiologic Studies
Depression Scale [19] (CES-D). A sample item is, “During
the past week, I was bothered by things that usually do not
bother me.”)e response is coded from 0 (rarely) to 3 (most
of the time) [20]. )e CES-D composite score is the sum of
20 scores. )e possible range is 0 to 60. If more than 4
questions are unanswered, no score is assigned. A score of 16
points or higher is considered depression.
Anxiety is measured by the 8-item Patient-Reported
Outcomes Measurement Information System (PROMIS)
Emotional Distress-Anxiety (short form) [21]. )e scale uses
a 7-day time frame and a sample item is, “I felt fearful.” )e
response is coded on a 5-point scale from 1 (never) to 5
(always) [21].
Mindfulness is measured by the 15-item Mindful At-
tention Awareness-Trait Scale (MAAS) [22]. )e MAAS is
designed to assess awareness and observation of what is
occurring in the present moment in participants’ everyday
experience. A sample statement is, “I could be experiencing
some emotion and not be conscious of it until sometime
later.” )e response is coded on a 6-point scale from 1
(almost always) to 6 (almost never). )e MAAS score is
computed as the average of 15 items.
Well-being is measured by Ryff’s 42-item Psychological
Well-Being (PWB) Scale [23]. Ryff’s PWB is a theoretically
grounded instrument that encompasses multiple facets of
psychological well-being, autonomy, environmental mastery,
personal growth, positive relations, purpose of life, and self-
acceptance. Since the inception of the scale thirty years ago, the
scale has been translated into 30 languages. A sample item for
the autonomy is, “I am not afraid to voice my opinions, even
when they are in opposition to the opinions of most people.” A
sample item for environmental mastery is, “In general, I feel I
am in charge of the situation in which I live.” A sample item of
personal growth is, “I am not interested in activities that will
expand my horizons.” A sample item of positive relations is,
“Most people see me as loving and affectionate.” A sample
item of purpose of life is, “I live life one day at a time and do
not really think about the future.” A sample item of self-ac-
ceptance is, “When I look at the story of my life, I am pleased
with how things have turned out.” For each item, the response
is coded on a 6-point Likert scale from 1 (strongly disagree) to
6 (strongly agree). )e composite score of each subscale is the
sum of its own 7 items and the composite score of the global
scale is the sum of 42 items. )e scale has been used in a
longitudinal follow-up of the US national sample [23].
Happiness is a global 0–10 happiness scale.
Only those who completed the first survey were asked to
complete the postintervention surveys. )ose who did not
complete the survey within a week of the first invitation were
sent e-mail reminders.
2.4. Blood Sampling. Survey participants were given the
option for blood biomarker evaluation. Informed consent
for blood draws was obtained, and the participant’s samples
were collected at the following time points: (1) preprogram
(up to 2 days before program began) and (2) postprogram
(within 2 days after program ended). Standard sterile ve-
nipuncture technique was used to collect 10mL of blood
divided into different sampling tubes for measuring anan-
damide, 1-AG, 2-AG, DEA, OLA, and BDNF.
For participant confidentiality, samples were deidenti-
fied with a code for sharing with individuals outside of the
study team. )e biomarker samples were sent immediately
to the analysis lab in Denver, Colorado. As anandamide is
quickly catabolized by Fatty Acid Amide Hydrolase
(FAAH), the fresh blood samples were centrifuged and
extracted plasma was frozen immediately to preserve and
accurately measure this biomarker.
2.5. Data Analysis. Repeated measures analysis of variance
(ANOVA) was used to compare preprogram (baseline),
immediately after program, and 1-month follow-up survey
responses; an unstructured variance-covariance matrix was
used. In the subset of subjects with biomarkers assessed,
paired t-tests were used to compare biomarkers for signif-
icant change from before meditation to after meditation.
Pearson correlation coefficients were used to evaluate the
associations between the changes in biomarkers and changes
in psychological states. In addition, the change in bio-
markers was categorized into two groups, including one
group where there was at least a 20% increase and another
where there was less than 20% increase. )e responses to the
psychological scale were separately analyzed for both of
these groups. A 5% significance level was used for all tests.
3. Results
3.1. Study Participation. )ree hundred forty-eight partic-
ipants completed the preprogram survey and 323
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participants completed the postprogram survey, resulting in
a 93% response rate. )e 1-month follow-up survey was
completed by 308 participants. One hundred and forty-two
participants volunteered for blood sampling for biomarker
assays before and after meditation retreat. Subject charac-
teristics are shown in Table 1.
3.2. Markers of Well-Being. Scores for depression (CES-D)
and anxiety significantly decreased from baseline to im-
mediately after retreat (P< 0.001; Table 2). )e mean CES-
D score was relatively low at baseline (10.3) and declined by
26%, mean decrease of 2.7 (SD � 8.6), and effect size of 0.31.
)e mean standardized anxiety score was also low at
baseline and declined by 23% at the immediate postretreat
survey, mean decrease of 0.46 (SD � 0.76), and effect size of
0.60.
Scores for mindfulness (MAAS), happiness, and psy-
chological well-being (PWB) increased significantly from
baseline to immediately after retreat (P< 0.001; Table 2,
Figure 1). Mean (SE) increases and effect sizes were 0.63
(0.85) and 0.75 for mindfulness, 2.0 (1.8) and 1.1 for hap-
piness, and 15.7 (20.8) and 0.75 for well-being. )ese im-
provements were maintained at the 1-month follow-up. )e
autonomy measure of PWB showed a continuous im-
provement, as PWB scores increased even more on the 1-
month survey compared with immediately after retreat
(P � 0.003; Table 2). All of these primary psychological
changes were statistically significant even after adjusting for
multiple testing.
Cronbach’s alpha values for the internal consistency
reliability of the psychological scales were all acceptable:
CESD� 0.90; anxiety� 0.94; mindfulness� 0.93;
PWB� 0.92.
3.3. Biomarkers. Endocannabinoids (anandamide, 2-AG, 1-
AG, DEA, and OLA) and BDNF were analyzed in 142
participants. Compared with baseline levels, all immediately
after retreat biomarker levels were higher (Table 3, Figure 2).
Some individuals had multiple-fold increases in ananda-
mide, and the effect size for biomarker changes ranged from
0.17 to 0.92. High interindividual variability was observed
among participants. Specifically, 2-AG increased signifi-
cantly (P< 0.001) by 2.0 ng/mL (SD� 2.8) with an effect size
of 0.71, and 71% of participants had an increase of at least
20%. Similarly, BDNF increased (P< 0.001) by 5945 pg/mL
(SD� 8414) with an effect size of 0.71, and 53% of partici-
pants had an increase of at least 20%.
Participants with increases in 2-AG levels larger than
20% after meditation from the baseline had larger increases
in mindfulness, happiness, and positive well-being (total,
autonomy, environmental mastery, positive relations, and
self-acceptance) scores (Supplementary Table (available
here)). Similarly, participants with increases in 1-AG or
total AG levels larger than 20% had larger increases in
happiness and positive well-being (total and self-accep-
tance for 1-AG, positive relations for total Ag; Supple-
mentary Table).
4. Discussion
In this large, prospective study, we showed that a short,
intense guided experiential meditation (BSP) significantly
decreases anxiety and depression and improves psycho-
logical well-being, happiness, and mindfulness and that
these improvements sustain for at least a month. For the first
time, we showed that objective blood biomarkers, eCBs
(anandamide, 1-AG, 2-AG, DEA, and OLA) and BDNF, all
increased following an advanced meditation, BSP, sug-
gesting a role for these mediators in the underlying
mechanisms of meditation. )e specific mechanisms linking
meditation to positive psychological effects have not been
well-characterized in the literature, and this research pro-
vides early evidence that the eCB system and BDNF are
significantly increased after advanced meditation.
Low blood levels of anandamide and 2-AG have been
reported in patients with depression [24]. Deficiencies in
anandamide can be associated with acute stress [25] and
increased pain [26]. Studies have related depression and
anxiety to the expression and/or functionality of cannabi-
noid type 1 (CB1) receptors and FAAH in brain areas be-
longing to the amygdala-hippocampal-corticostriatal neural
circuit, especially the frontal cortex in depression and the
amygdala in anxiety disorders [13]. Increasing patients’
anandamide levels is a potential solution for many ailments
including depression [27, 28], fibromyalgia [29, 30], in-
flammatory bowel disease [31–33], and cancer [34, 35]. Our
findings that meditation can increase blood eCB levels and
improve well-being suggest that meditation might be further
Table 1: Subject characteristics.
Race/ethnicity n (%)
Asian: Far Eastern 7 (2%)
Asian: Indian 243 (70%)
Asian: Middle Eastern 6 (2%)
Black (African American) 6 (2%)
Hispanic 14 (4%)
White Nonhispanic (Caucasian) 57 (16%)
Mixed race: Asian-White 1 (<1%)
Mixed race: others 4 (1%)
Other 5 (1%)
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explored as a treatment modality for anxiety and depression
and possibly even other diseases.
)e level of increase in eCBs following meditation was
large enough to be deemed clinically significant, as effect
sizes ranged from 0.77 to 0.90, and some participants had 2-
3-fold increases. )is is more than reported eCB increases
associated with moderate intensity aerobic physical exercise
[36] and sexual orgasm [37]. Modest increases (<40%) in
Table 2: Results of psychological surveys before and after a 4-day Bhava Spandana Program meditation retreat.
Psychological parameter
Baseline before retreat Immediately after retreat 1-month after retreat
N Mean (SE) N Mean (SE) N Mean (SE)
CES-D (depression) 348 10.26 (0.47) 323 7.55 (0.32)a 308 7.67 (0.37)a
Anxiety scale 342 1.93 (0.04) 312 1.48 (0.03)a 300 1.54 (0.04)a
MAAS (mindfulness) 346 4.14 (0.05) 320 4.77 (0.05)a 301 4.80 (0.05)a
Happiness score 342 6.20 (0.10) 312 8.23 (0.08)a 291 7.62 (0.09)a
PWB (well-being) total 342 187.3 (1.5) 312 203.0 (1.3)a 293 203.4 (1.4)a
PWB autonomy 30.08 (0.34) 33.14 (0.32)a 33.93 (0.31)a,b
PWB environmental mastery 28.49 (0.28) 30.88 (0.25)a 30.99 (0.26)a
PWB personal growth 35.23 (0.28) 37.18 (0.23)a 37.27 (0.25)a
PWB positive relations 31.99 (0.34) 34.91 (0.30)a 34.73 (0.32)a
PWB purpose in life 30.30 (0.30) 32.12 (0.27)a 31.85 (0.28)a
PWB self-acceptance 31.20 (0.38) 34.79 (0.31)a 34.77 (0.33)a
aSignificantly different from baseline value (P< 0.001), bSignificantly different from immediately after-retreat value (P � 0.003). All changes were statistically
significant even after adjusting for multiple testing. CES-D�Center for Epidemiologic Studies Depression; MAAS�Mindful Attention and Awareness Scale;



























































Figure 1: Mean with 95% confidence interval for depression (CESD), anxiety, focus (MAAS), and happiness at premeditation, post-
meditation, and change (post-pre). Focus and happiness increased significantly while depression and anxiety decreased significantly (all
P< 0.001). CESD � Center for Epidemiological Studies Depression Scale; MAAS�mindful attention and awareness scale.
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eCBs explain pleasurable effects of singing and exercise and
ultimately some of the long-term beneficial effects on mental
health, cognition, and memory [38]. Moreover, increases in
eCB levels with moderate exercise have been associated with
mood improvements in patients with major depressive
disorders, explaining the biological mechanism behind
mood enhancement with exercise in major depressive dis-
orders [39] and posttraumatic stress disorder [40].
Activation of CB1 receptors has been shown to increase
BDNF expression [41]. We demonstrated increased BDNF
levels following meditation, and our findings validate similar
observations from a previous Isha mediation program [18].
)is is notable as BDNF is associated with neuronal re-
generation [42–45]. BDNF deficiencies have been linked to
mental disorders such as depression [46, 47], bipolar dis-
order [46], and schizophrenia [48, 49]. While THC has been
shown to increase BDNF levels, this effect is mitigated by
even light chronic cannabis use [50]. )erefore, endogenous
activation of CB1 receptors through other ways, such as
meditation, would be necessary to have a long-lasting impact
on BDNF expression. Future studies might examine the
efficacy of meditation as a therapy for bipolar disorder,
schizophrenia, and other mental health conditions.
)e sustained positive impacts from meditation, even
one month after BSP, are encouraging. )e BSP participants
experienced persistent positive benefits from the short and
intensive BSP meditation, extending beyond an immediate
“high” or bliss feeling from increased eCBs. An intense
short-term negative experience can lead to diseases like
posttraumatic stress disorder; thus an intense short-term
positive experience might similarly lead to lasting positive
psychological consequences. Completion of Inner Engi-
neering program (level 1) and daily practice of Shambhavi
kriya is a requirement for BSP, and participants were en-
couraged to continue this daily practice after the BSP to
maximize potential benefits. Continued daily meditation
may have contributed to some of the sustained positive
results at 1 month after BSP in our study. Given certain
logistical constraints (some BSP participants were from
different states or other countries), we did not collect blood
samples to reassess biomarkers at 1 month. )is could be
evaluated in future studies.
Weak but positive correlations between biomarker
changes and changes in psychological measures, including
some interindividual variations, were observed in this study.
)e findings suggest that there are interindividual variations
Table 3: Changes in blood biomarkers (endocannabinoids and BDNF) following a 4-day Bhava Spandana Program meditation retreat.
Biomarker N
Baseline before
retreat Immediately after retreat Change P value Effect size Participants (%) with>20 (%) increaseMean (SD) Mean (SD) Mean (SD)
Anandamide (ng/mL) 142 0.58 (0.16) 0.75 (0.21) 0.17 (0.22)
<0.001
0.77 59
2-AG (ng/mL) 142 2.2 (1.6) 4.2 (3.1) 2.0 (2.8) 0.71 71
1-AG (ng/mL) 142 4.4 (3.3) 14.3 (11.3) 9.8 (10.6) 0.92 92
Total AG (ng/mL) 142 6.6 (4.8) 18.5 (14.2) 11.9 (13.2) 0.90 89
DEA (ng/mL) 142 0.21 (0.07) 0.27 (0.09) 0.06 (0.07) 0.86 60
OLA (ng/mL) 142 22.4 (36.5) 30.9 (45.4) 8.5 (50.7) 0.048 0.17 52
BDNF (pg/mL) 142 17152 (8048) 23097 (5526) 5945 (8414) <0.001 0.71 53
1-AG� 1-arachidonoylglycerol (degradation product of 2-arachidonoylglycerol); 2-AG� arachidonoylglycerol (unstable in plasma without pH adjustment);
total AG� sum of 1-arachidonoylglycerol and 2-arachidonoylglycerol (this is the value that should be used for the estimation of endocannabinoid 2-AG);






































Figure 2: Mean with 95% confidence interval for anandamide (ng/mL) and BDNF (pg/mL) at premeditation, postmeditation, and change
(post-pre). Both biomarkers increased significantly (P< 0.001). BDNF� brain-derived neurotrophic factor.
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in objective biomarkers, similar to variation in experiences
and happiness levels. Because of the disparity in subjective
experience and physiological responses, the benefits and
expression of biomarkers from meditation may vary be-
tween individuals. )is needs further study to explore the
interindividual variations in subjective and biomarker re-
sponses in people simultaneously participating in a medi-
tation program. Factors such as genetics/epigenetics, gene
expression, and corresponding psychological health may
explain these interindividual variations.
Strengths of this study are prospective design, relatively
large number of meditators participating simultaneously in
validated psychological surveys and blood biomarkers
before and after meditation, hypothesis-driven approach to
mechanistically associate the beneficial effects of medita-
tion with simultaneous objective biomarker assay associ-
ations, use of validated scales for sustained psychological
benefits of meditation for up to 1 month, and generaliz-
ability of the findings as the study meditators had diversity
in terms of age, sex, race, and ethnicity. Limitations in-
cluded lack of 1-month postretreat biomarker assessment,
as discussed above. Additionally, the 4-day BSP retreat had
multiple daily meditation sessions, and the “immediately-
after-meditation” blood samples were actually collected
after the entire program. Because eCBs (particularly
anandamide) are highly labile, biomarker expression would
likely have been even higher if samples had been collected
during the retreat. )e study population had low baseline
levels of anxiety and depression; therefore, differing results
might be obtained by analyzing the effects of meditation on
patients with psychological disorders. Finally, participants
were not surveyed on postretreat meditation or other ac-
tivities that may have contributed to the sustained long-
term benefits.
Since the meditators in this study were prospectively and
objectively followed over 3 time points, each individual
essentially served as his/her own control. To rule out a
placebo effect, we analyzed objective biomarkers in addition
to self-reported psychological changes. )e lack of a sepa-
rate, matched control group may be viewed as a study
limitation. However, the significant changes in objective
biomarkers and the sustained psychological benefits (despite
only a brief meditation retreat) strongly support that this is a
true effect rather than a placebo. )is pilot study provides
evidence to support future larger studies (including a control
group) with longer-term follow-up to assess the persistent
benefits of meditation.
More research is needed to understand the role of the
eCB system in the mechanisms of meditation. In future,
the effects of meditation may be replicated through
pharmacologic intervention, as FAAH inhibitors can
reduce anandamide degradation. Inhibition of FAAH has
been considered as a treatment option for anxiety and
other psychological disorders [25, 51–54]; however, a
clinical trial of one compound in 2016 caused severe
adverse effects including one death [55]. Meditation re-
mains a simple and safe option to improve well-being and
benefit individuals with depression, anxiety, and other
disorders.
5. Conclusion
An intense 4-day guided Isha meditation retreat significantly
decreased depression and anxiety while improving happi-
ness, mindfulness, and psychological well-being. Increased
blood endocannabinoids and BDNF were also observed
immediately after the intense meditation, potentially
explaining the underlying mechanism behind the im-
provements in happiness and other psychological benefits.
)e psychological effects of the meditation retreat were
sustained for at least 1 month. Meditation might serve as a
simple, organic, nonpharmacological, and effective low-risk
therapy or a prevention strategy for depression and anxiety,
while improving happiness and well-being. Future studies
are needed to investigate the role of the eCB system as
mediators of the positive effects of meditation, the sustained
benefits of meditation over longer-term, and reasons for





ANOVA: Analysis of variance
BDNF: Brain-derived neurotrophic factor
BSP: Bhava Spandana Program
CB1: Cannabinoid receptor type 1




FAAH: Fatty acid amide hydrolase
IL: Interleukin
MAAS: Mindful attention and awareness scale
OLA: Oleoylethanolamide
PWB: Psychological well-being scale
THC: Tetrahydrocannabinol
TNF: Tumor necrosis factor.
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